Access includes Asimov’s CHO Edge cell line development platform and Cytiva’s HyClone™ media and feed solutions, along with Cytiva’s Fast Trak™ process development services.

The new offering will provide seamless access to Asimov’s CHO Edge cell line development platform, Cytiva's HyClone media and feed solutions, and Cytiva’s Fast Trak process development services.

The risk of developing blood cancer increases with age. The finding that a molecule from gut bacteria plays a part points to ...

Tia Zakher says she stopped washing her face, even with water, back in March. She's shared the results online and is getting ...

The Company has been selected to deliver an oral presentation on the translational data from its Phase 1 clinical trial of FT522, an off-the-shelf, CD19-targeted CAR NK cell product candidate, in ...

The Company has been selected to deliver an oral presentation on the translational data from its Phase 1 clinical trial of FT522, an off-the-shelf, CD19-targeted CAR NK cell product candidate ...

A team of evolutionary scientists, dermatologists and wildlife specialists affiliated with several institutions in Japan, ...

Clinical trials are underway that demand us to rethink menopause—and whether or not women actually need to go through it.

These are the things you can control, and yes, that's where he disrespected the process, and that's where a lot of the NFL was very turned off by Shedeur Sanders." Floria also drew comparisons ...

About SENTI-202 SENTI-202 is a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy product candidate designed to selectively target and eliminate CD33 and ...